FDA Warns Trial Investigator for IRB, Consent Form, Protocol Violations
The FDA handed a cardiac surgeon at Washington, D.C.-based Washington Hospital Center a warning letter for not having institutional review board (IRB) approval when recruiting some patients into a clinical trial.
During an Aug. 24 to Sept. 15, 2011, inspection, investigators found five subjects recruited into an investigational drug study had signed consent forms indicating the trial was IRB-approved. But according to the Sept. 28 letter posted recently online, IRB approval had expired in early May of that year. Patients were still being recruited through July, the letter adds.
Avoid making this or other costly mistakes in your next trial.
Receive practical and easy-to-use information that will guarantee further understanding of study design and aid in approvability of an investigational product. Plant to attend this Wednesday conference. Register today!
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!